Overview
MICOT PHARMA-B (2335)
Shaanxi Micot Pharmaceutical Technology Co., Ltd. engages in discovery, development and commercialization of bi-/multi-specific peptide drugs. The company engag...
- Open
- 20.500
- High
- 22.820
- Low
- 18.900
- Prev. Close
- 20.580
- Volume
- 4.57M
- Turnover
- 96.33M
- Avg Price
- 21.088
- Bid/Ask Ratio
- 92.13%
- Amplitude
- 19.05%
- 52wk High
- 45.040
- Volume Ratio
- 7.30
- Turnover Ratio
- 1.79%
- 52wk Low
- 10.800
- HK Mkt Cap
- 5.06B
- Market CapHKD
- 6.57B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -1.26
- EPSDynamic
- -1.60
- EPSStatic
- --
- BVPS
- 3.28
- P/B
- 6.03
- HK Shares
- 255.39M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 331.74M
- Min lot size
- 200
- Currency
- HKD
MICOT PHARMA-B Analyst Rating
View moreForecast & Rating
Aug 31, 2026- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 1
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Micot Pharma-B traced a spike-and-fade session: after touching HK$22.66 in the morning, it slid to HK$19.44 by 14:44 BJ and closed at HK$19.80, down 3.79% from the prior close of HK$20.58 on about HK$96 million turnover. The impulse from completing MT1013 Phase III follow-up is being digested, with a 15.72% weekly drawdown and a fresh 8% drop headline extending the retreat. Fundamentals remain pre-revenue: Q2 EPS -HK$0.5089, net loss HK$133 million widening 397.61% YoY, operating loss HK$92.8 million, PE -15.65 and PB 6.03. The price sits above MA20 of HK$17.16 but below MA60 of HK$21.48, down 46.34% YTD, 56.04% below the 52-week high of HK$45.04 set on 15 July and 83.33% above the 1 November low of HK$10.80. Though the MT200605 ethics approval, the RMB 960,000 government grant and the H-share buyback mandate remain in place.
- Nov, 13
After a cluster of updates — including multiple drug development announcements, completion of treatment and follow-up for all MT1013 Phase III participants, ethics approval and RMB960,000 in government funding for MT200605, and an H-share buyback mandate — Micot Pharma (2335.HK) surged in the morning to an intraday high of HK$25.16 but reversed in the afternoon to close at HK$20.68, down 4.6% from the previous close of HK$21.68. The stock opened at HK$21.70, rose from HK$21.80 in the morning session to HK$24.80 by 11:59 BJ time, then hit a session low of HK$19.55 at 15:19 BJ time, producing a 25.9% intraday range on 10.59 million shares and HK$240.3 million turnover. The close was 17.8% below the day's high, effectively erasing the morning gain. Latest financial and valuation data were unavailable, so the HK$20.68 close can only be positioned near the lower end of the day's HK$19.55–HK$25.16 range. Though turnover of HK$240.3 million points to clear disagreement between buyers and sellers, the next move still depends on how those announcements translate into execution.
- Nov, 12
Micot Pharma-B rose 1.78% to HK$21.70, rebounding from a low open of HK$20.80, as news that all participants had completed treatment and follow-up in the MT1013 Phase III trial drove an intraday surge of as much as 12% to HK$23.92 before the stock retreated into the close; the intraday range ran from HK$20.62 to HK$23.92, leaving the close below the afternoon peak but above the session low. The company also received RMB960,000 in government funding for MT200605 research and disclosed an H-share buyback mandate, but Q2 2026 net loss widened 397.61% year on year to HK$133.3 million, EPS was -HK$0.5089, operating loss reached HK$92.8 million and revenue was not disclosed, tempering the advance. At HK$21.70 the stock is 41.19% lower YTD, 51.82% below its 52-week high of HK$45.04 and 100.93% above its 52-week low of HK$10.80; it sits above MA20 of HK$17.08 but just below MA60 of HK$21.82, with market value around HK$7.20 billion, PB 6.61 and turnover rate 4.07%. Though the Phase III completion is a milestone, the timing of registration and commercialization remains to be seen.
- Nov, 11
Micot Pharma-B reversed early strength, opening at the 23.32 HKD session high before sliding one-way to a 21.20 HKD afternoon low and closing at 21.30 HKD, roughly 7.9% below the prior close of 23.12 HKD on 87.98 million HKD turnover, as investors booked profits on a two-day run of about 18% (including single-day gains of 12% and 6%) driven by news that all participants had completed treatment and follow-up in the MT1013 Phase III trial. At 21.22 HKD the shares still hold above the 20-day average of 16.80 HKD but have lost the 60-day line at 21.99 HKD, sit 52.9% below the 52-week high of 45.04 HKD, are down 42.5% year-to-date yet remain 96.5% above the 1 November low of 10.80 HKD, while a PB of 6.47 and negative PE of -16.78 reflect a still loss-making profile. Though a RMB 960,000 government grant for MT200605 research and an H-share buyback mandate remain in the background.
- Nov, 10
Micot Pharma-B spiked to HK$25.52 in the morning session after the company said all enrolled participants had completed treatment and follow-up in the MT1013 Phase III trial, but the stock gave back the entire gain to close at the day's low of HK$23.02, down 5.73% from HK$24.42 on 7.90 million shares worth HK$191.7 million, a clear spike-and-fade pattern. The move extends a run driven earlier by ethics approval from the lead site for the MT200605 Phase III trial and a RMB960,000 first tranche from the National Key S&T Program, which contrasts with a Q2 2026 net loss of HK$133.3 million, 397.61% wider year on year, EPS of -HK$0.5089 and ROE of -48.83%. At HK$23.02 the shares sit above the MA20 of HK$16.69 and the MA60 of HK$22.14, yet remain 37.62% lower year to date and 48.89% below the July 15 52-week high of HK$45.04. Though the rebound from the November 1 low of HK$10.80 has already more than doubled, leaving room for short-term profit-taking.
News
Market Movers · Micot Pharma tumbles 8%
Market Movers · Micot Pharma climbs 6%
Weekly Review · Weekly Recap | MICOT PHARMA-B -15.72%, MT1013 update fades into sell-off
Market Movers · Micot Pharma falls 6% in Hong Kong trading
Market Movers · Micot Pharma surges 12% on multiple drug development updates
Market Movers · Micot Pharma surges 12% as MT1013 Phase III trial completes follow-up
